Clinical and pathological data from patients with CC (n = 300) who underwent surgical resection at a single tertiary hospital were retrospectively collected to evaluate presence of MS components and diagnostic criteria, CC phenotype and disease outcomes. Thus, our aim was to investigate whether the presence of MS or any of the MS individual components could provide prognostic information on tumor phenotype and survival outcomes. However, whether the cluster of metabolic changes that define MS also influence CC prognosis remains unclear. Metabolic syndrome (MS) is recognized as a risk factor for colon cancer (CC). 9Department of Surgery, Faculty of Medicine, University of Porto, Porto, Portugal.8General Surgery, Hospital de Pedro Hispano – Unidade Local de Saúde de Matosinhos, Senhora da Hora, Portugal.7iGo Department, CINTESIS-Center for Research in Health Technologies and Information Systems, Porto, Portugal.6Medical Oncology Department, Centro Hospitalar Universitário do Porto, Porto, Portugal.5Unit of Oncobiology Research, Unit for Multidisciplinary Biomedical Research (UMIB) of Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.4Centre for Obesity Research, University College London, London, United Kingdom.3Endocrine, Cardiovascular & Metabolic Research, Unit for Multidisciplinary Biomedical Research (UMIB) of Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.2School of Health, Polytechnic Institute of Porto, Polytechnic of Porto, Porto, Portugal.1Pharmacy Department, Centro Hospitalar Universitário do Porto, Porto, Portugal.Monteiro 3,4*, António Araújo 5,6 and Gil Faria 7,8,9